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Abstract
Background: Peripheral vascular diseases have a significant impact on functional quality of life. Previous research
has demonstrated the complex, limiting and costly economic implications of these conditions such as lower limb
ulceration chronicity and ischaemic amputation. These complex, limb and life threatening conditions demand the
development of novel interventions with objective research as part of that development. Hence, a novel
intermittent negative pressure medical device in the form of a wearable boot (FlowOx™) was developed. As part of
the development process, this study aimed to explore patient and clinician opinions of the boot.
Methods: A qualitative approach was used to collect patient and clinician experiences in Norway. An advisory
group informed the semi-structured questions used in seven patient interviews and one clinician focus group (n =
5). The data were recorded digitally and transcribed verbatim. Patient and clinician data were analysed as distinct
groups using a thematic process.
Results: Data analysis resulted in five themes from the patients which gave insight into; the impact of the disease
process; practicalities of using the boot, positive experiences of use; perceived outcomes; reflecting on use. Six
themes were created from the clinicians. These gave insight into; ideal outcomes and how to measure them; ways
to potentially use the boot; using research in healthcare; positives of the device; observed effects and next steps;
potential improvements to the device.
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Conclusion: This study provides insight into the experiences and opinions of FlowOx™. Patients and clinicians were
positive about the device due to its ease of use. Those patients with peripheral arterial disease experienced
significantly more benefit, especially for ischaemic ulceration than those with a chronic venous condition. Clinicians
placed value on the patient reported outcomes in the treatment decision-making process. This preliminary study
into experiences of FlowOx™ use provides valuable feedback that will inform design modification and ongoing
research into implementation points and prospective user groups. FlowOx™ demonstrates potential as a
conservative therapy offering users a convenient, home use, self-care management solution for improving
symptomatic peripheral arterial disease and quality of life.
Background
Peripheral arterial disease and chronic venous
aetiological conditions are a global problem in an ageing
population [1, 2] with peripheral arterial disease carrying
high associated risks of cardiovascular morbidity and
mortality [3–6]. Walking-associated claudication pain
proves a frequent symptom of peripheral arterial disease,
yet many are asymptomatic and consequently unaware
of disease presence [7, 8]. Lower limb ulceration, gan-
grene or prolonged rest pain classifies as chronic limb-
threatening ischaemia [9], which requires prompt revas-
cularisation to prevent limb loss [9, 10]. Although wide-
spread in its epidemiology, peripheral arterial disease
remains largely underdiagnosed and hence undertreated
[11–13]. The cost of treatments for ulceration alone
continues to prove a significant economic burden and at
a cost to developing countries that is estimated between
1 and 3% of their total health expenditure [14–16]. For
the patient, lower limb vascular compromise has been
shown to significantly affect quality of life by reducing
everyday functional capacity and instilling a growing un-
certainty regarding illness, treatment and long-term
health status [17–21].
The number of patients who have chronic venous dis-
ease are predicted to increase significantly in the coming
years and decades. The global burden of chronic venous
disease uses approximately 2% of healthcare budgets,
[22–24]. The disease progression rates are reported to
be 4% [25, 26] and varicose vein procedures, are pro-
jected to increase by 60% by 2021 [27]. The venous leg
ulcer is a common type of ulcer in the lower extremity
[28]. Venous leg ulcers accounts for 70–80% of ulcers
presenting for evaluation and treatment to a range of
healthcare disciplines. The prevalence of venous leg ul-
cers is up to 2% of the population and, importantly, in-
creases to 5% of individuals over the age of 65 years old
[29, 30]. Europe has up to 2.2 million people affected by
venus leg ulcers, and over 6 million individuals are af-
fected in the United States [31]. Although appropriate
wound care and compression therapy can be effective in
healing, the recurrence rates are high, these can be as
high as 50–70% at 6 months [30].
With a last reported chronic limb threatening ischae-
mia regional prevalence in Norway of 0.24 to 0.26% in
40–69 year olds [32], increased efforts have been placed
on implementing health promotion strategies within
identified at risk populations [33, 34]. However, there
are no studies or reports that have described a recent
change in the prevalence of chronic limb threatening is-
chaemia. In the Norwegian registry for vascular surgery
(NORKAR), over the last 5 years an increased share of
patients treated for chronic limb threatening ischaemia
have peripheral arterial disease. It would be interesting
to examine the context and evaluate the health strategies
in depth.
Over the last two decades, Scandinavian studies show
reductions in major amputation rates and increases in
endovascular procedures, although Norwegian regional
disparities occur [35–37]. In line with international
trends [38], the studies reveal an improvement in dia-
betic foot health [37], increased chronic limb threatening
ischaemia awareness, optimal treatment strategies with
better organised and widespread vascular surgical
services.
However, sub-optimal results for limiting deterioration
have been found in relation to increasing risk-factor
awareness and lifestyle modification [39–44]. Therefore,
effective and acceptable therapies are needed to improve
circulation and promote wound healing. Self-
management through targeted behavioural change
proves a central element in vascular risk management
[45]. Exercise programmes yield improvements in pain-
free walking which may improve quality of life [46], still
these prove unsuitable with active ulceration and are
hindered by poor uptake and accessibility [47].
The use of directly applied negative pressure wound
therapy has shown some improvements for chronic
wounds [48, 49]. Negative pressure wound therapy has
successfully been applied in a primary and home-care
setting [50]. The introduction of a Norwegian hospital
wound support team network has improved the clinical
efficacy of the home care services and reduced the need
for consultations at the hospital [51]. This model of
home intervention, supported by a hospital network
team, can be applied to other devices [50]. The recent
Sedgwick et al. Journal of Foot and Ankle Research           (2021) 14:61 Page 2 of 13
development of a novel device (FlowOx™ Otivio, Norway,
Fig. 1), that applies intermittent negative pressure to the
lower leg but not directly to the wound, has demon-
strated improvements in both micro and macro-
circulation and improved healing in hard-to-heal
wounds [51, 52]. The positive effects of intermittent
negative pressure have been described to be caused by
an increased arteriovenous pressure gradient, shear rate,
and blood flow fluctuations, leading to improved endo-
thelial function [53, 54]. Data published after this quali-
tative study was undertaken, has revealed improvements
in pain-free walking distance after 12 weeks of intermit-
tent negative pressure-treatment [55] and in a follow-up
study of 24 weeks of intermittent negative pressure-
treatment, both pain-free and maximum walking dis-
tance increased [56]. FlowOx™ is a CE marked medical
device intended for use by patients with peripheral vas-
cular disease. Such medical devices are becoming more
known for home use; therefore safety, suitability and ac-
ceptability must be established [57, 58]. Therefore, this
qualitative study aimed to gather patient experiences of
using this self-use intermittent negative pressure medical
device in relation to its usability, its design and value.
Further, it aimed to gather clinician opinion on the clin-
ical effects and benefits, financial benefits and critical
price points in Norway healthcare.
Methods
Ethics
This qualitative study was granted ethical approval by
the University of Salford, School of Health Sciences Eth-
ics Committee (HSR1617–31) and the Regional Com-
mittees for Medical and Health Research Ethics,
Norway.
The intervention
FlowOx™ (Fig. 1) provides an intermittent negative pres-
sure to the lower limb and foot in the form of a wearable
boot. The leg and foot are suspended inside and held
with medical grade pads. A silicone seal is pulled over
the leg to allow a negative pressure to be established.
The pressure is set and cycled intermittently with input
from the control box. The system was prescribed by cli-
nicians for use by patients for a recommended 2 hours
use per day, however, this was not controlled, and some
participants used the device for longer than 2 hours. At
the point of data collection the system was provided for
patients to use through funded research with some treat-
ment costs paid by the company and grant funding (Re-
search Reimbursements). Continued use of FlowOx™
beyond the research was paid for by patients, in some
cases this cost was supplemented by the Norwegian
healthcare system which provides an individual allow-
ance for medical expenses.
Participants and recruitment
The FlowOx™ treatment was not widely prescribed,
therefore a purposive sample of patients and clinicians
with experience of its use across two hospital sites in
Norway (Oslo & Trondheim) were invited to participate.
Potential participants who had used the device for a
minimum of 6 months were given information sheets de-
tailing the aim and the voluntary nature of the study. In-
formed consent was taken from patients prior to
interview and from clinicians prior to the focus group.
Seven patients agreed to participate in an interview
(Table 1). Two patients were solely Norwegian speaking,
whilst five agreed to an English-speaking interview. An
interpreter was present during interviews to eliminate
unforeseen language barriers. Five clinicians from vascu-
lar clinical teams at two hospital sites were invited to
participate in a focus group. Clinicians were members of
vascular surgical staff (n = 3) and clinical research (n =
1) from Oslo and vascular surgical staff (n = 1) from
Trondheim. Anonymity was achieved by using partici-
pant numbers during data collection and analysis. All
audio files, transcripts, data analysis and data containing
patient and clinician information were stored on a pass-
word protected server at the University of Salford.
Data collection
An advisory group for this qualitative study was formed
and comprised of members of the main study which fo-
cussed on quantitative outcomes of the intervention
[59]. Members included the Principal Investigator (FH),
the quantitative research team (DP, SA) and qualitative
researchers (AW and CS) informed the semi-structured
questions for the face to face patient interviews aimed at
understanding patient experiences and opinions on the
usability of FlowOx™. The group also informed the focus
group questions that sought to gain clinician opinions
about the effectiveness of FlowOx™ as a treatment for
peripheral arterial disease and/or ulceration, including
cost implications.
Patient interviews were conducted at the participants
convenience either at the hospital sites or in their own
Fig. 1 FlowOx™ device and components (image courtesy of Otivio
AS, Oslo, Norway)
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homes. Interviews were carried out by the main re-
searcher (CS), a UK Podiatrist and a research assistant
with clinical experience of patient interviews and man-
agement of lower limb vascular conditions. Question
topics explored patients experiences of use, benefits and
barriers, thoughts on design and cost value, additional
treatments and recommendations for other users.
The clinician focus group was conducted at the Oslo
hospital site and facilitated by the main researcher (CS).
The choice of a focus group at the Oslo hospital was
pragmatic to allow staff to contribute whilst being avail-
able for emergencies. Question topics explored experi-
ences of clinical effects and benefits, research
reimbursements and critical price points in Norway
healthcare.
Data were collected with digital audio recording (WS-
853 Digital Voice Recorder, Olympus) and supplemented
with field notes. Patient interviews lasted between 12
and 34min and the clinician focus group lasted 42 mins.
The recorded data were translated from Norwegian to
English as applicable and then transcribed verbatim
using an independent service (Go Transcript, UK).
Data analysis
A pragmatic qualitative descriptive approach [60] with
thematic analysis [61] was utilised. The analytical re-
searchers (CS and CG) familiarised themselves with the
data and generated initial codes by listening to audio re-
cordings and re-reading interview and focus group tran-
scripts. The addition of a second researcher (CG) to the
initial analysis added to the credibility of the findings.
Nvivo (Nvivo 12 Pro, QSR International) provided a pro-
cessing platform for analysis. Emerging themes were
then developed and refined through an individual review
process that sought to underpin central concepts, reflect
the descriptive and explicit content of the data [61] and
validate results from participants transcripts. A natural-
istic approach allowed researchers to gain rich descrip-
tive experiences and opinions of the medical device used
in the natural environment herein, the “home” [60, 62].
To reduce subjectivity and enhance rigour, the main
researcher (CS) also undertook the analysis of focus
group data with the second researcher (CG). An ex-
perienced qualitative senior researcher authors (AW)
verified the analysis and results and then consensus
was achieved. Extracts from the transcripts were used
to illuminate the themes and to demonstrate truthful-
ness Figs. 2 and 3.
Results
Patient interviews
Theme 1. Impact of the disease process
Experiences of using FlowOx™ revealed recurrent dia-
logue from patients that focused on symptomatic
changes to lower limb health. Personal accounts
highlighted significant functional daily living changes
from diagnosis and through disease progression. Pain
levels dictated physical activity limits:
“I could walk for some distance, and then I had to
stop because it hurt so much.” [p3]
The experience of pain also affected the quality of
sleep:
“It was like I put my toes in hot water. So, I had to
go get up once every hour each night to walk around,
slow it down … ” [p6]
Most described treatment for ulceration and were within
various stages ranging from static healing to complete
resolution.
For the two participants with current venous ulcer-
ation they reported discomfort as p4 reveals,
“ … I get this nagging feeling in my leg which is un-
comfortable and painful when the dressing sticks to
it.”
Dialogue revealed how vascular compromise with per-
ipheral arterial disease led to clinician discussion of the
risks of amputation:
Table 1 Patient demographics
Patient 1 2 3 4 5 6 7
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“There is the danger that I may lose a leg … ” [p1]
The risk of limb loss for those with peripheral arterial
disease ultimately led to experiencing feelings of fear
and worry:
“So, I was afraid that I was going to lose both of
them.” [p5]
“To go from being physically fit to talking about an
amputation in a course of six months did things with
me. It did do things with me mentally.” [p6]
Theme 2. Practicalities of using the “boot”
Description and demonstrations of how practical the de-
vice was to use emerged as a prominent theme. Most
found the device comfortable and easy to use:
“Nothing difficult, ‘cause everything was easy.” [p4]
All were able to use the device independently:
“It’s an easy device to use. Just put it on and press
the button and forget about it.” [p2]
Some practical usage issues were revealed with the seal
component. Pulling on the seal proved difficult for some.
It was postulated that the elderly may have difficulties
with the design.:
“So there is some difficulty getting hold of it to get it
over there...” [p3]
“I think that elderly people will not manage to use
this without having home care or something similar
… ” [p7]
Differences in the seal material lead to an increase in
size, corrosion and problems achieving maximum
pressure:
“It started failing because it just got a little bigger
and bigger.” [p1]
Fig. 2 Patient Interviews: Primary and secondary themes
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“The machine shows leakage.” [p2]
Views on whether personal health insurance would
cover costs for this novel device were mixed and with
one who was unsure:
“I don't know. I haven't asked. But I really hope they
will do it, because I think many people can have an-
other life with it.” [p2]
During device use, patients’ experienced various sensa-
tions within the leg and foot described as tingling and
pain relief:
“And if I did feel discomfort, a lot of discomfort, it
was the device that I actually used. So, if I really
was having a lot pain, I used to put my foot into the
boot and it did have an effect. Because it wasn't
painful … When it was bad it was what I used to
ease and comfort.” [p5]
The time taken to use the device, its inability to be a
mobile device, the space taken to accommodate it and
its sound became a burden for some:
“Three hours a day is three hours a day. And it's
three hours missed to do something else.” [p4]
All described accommodating the device in their homes
and around routines. One patient described using the
device for longer than the prescribed daily 2 hours:
“ … I was a little bit desperate at that time, so I was
willing to push the boundaries probably. Okay, you
know and I did use, I have probably overused it … I
took control of it. I did. And being able to decide for
myself that I was going to overuse the boot really
was a decision that I'm quite happy that I did as
well. Without actually knowing the technical or the
medical information behind it. It was a chance I
took.” [p6]
Theme 3. Positive experiences
Positive experiences from device use emerged through-
out most interviews:
“I am a 100% happy up to now … I have nothing
negative.” [p6]
Two patients gave lengthy detail to the changes to their
lower limb health during device use and that had re-
sulted in a complete symptomatic reversal, varying de-
grees of wound healing and complete wound resolution:
Fig. 3 Clinician Focus Group - Primary and secondary themes
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“ … I understand that it was this block in the vein
that was coming out. That was amazing … my usual
doctor she couldn’t understand what’s happening.
She was just wow … And the feeling was fantastic,
too, because then I realised that my toes was safe.”
[p6]
“I'm warm and good in my leg and my foot which
was dead.” [p1]
Some described fond feelings for the device and relief in
avoiding amputation. Continued use was described as
necessary to prevent symptom deterioration:
“So now it's not repairing but keeping it as it shall
be.” [p4]
“A little week without and my foot is going to be big-
ger.” [p7]
These positive health improvements were described as
having a significant impact on the ability to carry out
daily tasks:
“I couldn't walk … I had to use the wheelchair all
the time, but now I can walk, I can do different
things. “I am more like a normal person." [p2]
“I do everything which I could do before, so, my life qual-
ity has been very improved through this project.” [p5]
Theme 4. Perceived outcomes
Outcomes included improved healing, circulation, and
pain reduction.
“I think the healing may have come quicker because
of it. I cannot say why, but, why I think so, but that's
what I feel. I feel that everything … all the wounds
were healed, eventually. And I think that healing
process was a little bit quicker because of that.” [p6]
However, dialogue emerged from one patient with
chronic venous ulceration experiencing minimal
improvement:
“Maybe in the start in the first 14 days, my head
thinks … It was a little tiny better, but then it all
stopped.” [p4]
One patient remained unsure as to whether observed
improvements were due to device use alone:
“I wish I had the information to say it was the boot
that did that. I don't have that, and I don't know if
anybody does, to be honest. If you take it in terms of
where I was … and what was then introduced in my
treatment from that period and after. There was
only one change in my treatment, and that was the
usage of the boot. It wouldn't be wrong to insinuate
that the boot has had a very positive effect, if all, to
my situation.” [p6]
For those with some or minimally perceived benefit,
there remained a level of optimism for further use:
“I want it to work.” [p5].
Theme 5. Reflecting on use
The participants recommendations were a reflection on
the potential value of device for others:
“Well, as time goes by one is willing to try almost
anything. I could not guarantee they would benefit
from it, but I would be recommending it because of
what experience that I've had.” [p1]
With current recommendation being implemented
through social media, chat forums and casual discussion:
“There is a lot of people out there that have big
problems. Big, big problems. I have spoken to them,
and I have posted up my treatment. The thing that
has always pushed forward which is the difference,
which they don't have out there, is this treatment
boot. There is interest for it. And people will, when it
comes to your life, it is about being functional. If
you're not functional it just ‘disabilitates’ everything
else that's in your life.”[p4]
Views on how much they were willing to pay along with
marketing suggestions for the device were mixed:
“So monetary wise it’s certainly is worth a lot in
terms of improving people’s functionality in their
everyday life … it is a foot saver, you could say.” [p5]
"I call it the wonder machine."[p4]
“I can't set a price on it because it saved my life. It
gave me my life back, in a way, so for me it's …
priceless … one suck and you're hooked.” [p1]
Clinician focus group
Theme 1. Ideal clinical outcomes and how to measure them
Clinician experiences from prescribed use revealed a
range of desired clinical outcomes, specifically saving
limbs, relieving pain and wound stabilisation:
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“I think it’s limb salvage … to save limbs.” [p5]
“I think the pain scale of the patient is an important
aspect of this, if this improves the pain from the
ulcer in any way, simply for the QoL for the patient.”
[p2]
“ … stop the progression of the ischaemic wound.”
[p1]
Clinicians described clinical methods used for measuring
device efficacy and effectiveness from wound size, pain
scales and blood flow. Some gave detailed accounts as to
how traditional clinical methods used to measure blood
flow may not provide efficacious results:
“There is a study where they have done training on
claudicants, where they have done an exercise pro-
gram and where they have clinically a longer walk-
ing distance, which with no benefit at the ankle-
brachial index for example. So, it’s an indication
that maybe these measurements are not done neces-
sarily reflect the clinical reality.” [p2]
“If you have wound healing and all the other param-
eters will tell you that there is no change, I would
still continue using the boot.” [p4]
Clinicians suggested that assessing small vessel blood
flow may be more indicative of device effects:
“If you’re looking for a minimal effect it could maybe
be to measure skin blood flow with laser doppler.”
[p3]
“The boot has not necessarily an effect on the big
vessels, it's more on micro level.” [p5]
Theme 2. Ways to potentially use “the boot”
Opinions revealed a need to find the best patient group
for the device:
“I think hopefully over time we'll be able to select the
patient group that will have a benefit from this ra-
ther than all of them, because I don't think every-
body will have a benefit of the boot.” [p2]
The potential need to discover when in the disease
process to use the device was also suggested. One com-
ment highlighted that perhaps the trials happening now
were too late:
“Also, since this is a new equipment, there is a
chance that some of the patients have come too far
in the process. It's important to be aware that they’re
maybe too late. In my opinion, many of the patients
we have tested it on so far, it's actually too late, so
then it would end in amputation anyway.” [p3]
In contrast, the device was also implicated as having the
potential to provide a last option for patients:
“I think that the FlowOx™ boots could be a promising
supplement to patients who basically have reached
the end of the line.” [p2]
Clinicians postulated that the device has potential to be
used with other patient groups, such as those with vaso-
spastic disorders and pressure ulceration. It was also
suggested that device effect on infection and safe use
during sleep could be further investigated:
“The treatment of antibiotics could also in theory
have been more effective using this system, if you, in
that way, can get the antibiotics closer to the bac-
teria in the wound by using the system … ” [p3]
Theme 3. Using research in healthcare
Research in Norwegian healthcare was described as re-
quiring rigorous testing of new medical interventions to
provide the evidence to secure funding:
“What we need to work on is developing new
methods maybe in a high-volume centre and then
when this is proven, try and get it out to the more
peripheral areas.” [p2]
Research was highlighted as essential to improve out-
comes for patients:
“We have to try out new equipment and new devices
and be in the research to see if we can improve the
outcome for our patients where there is no other
hope for them.” [p1]
The practicalities of facilitating new research in hospitals
and with novel interventions was reported by clinicians
as more receptive in those hospitals with academic links:
“It depends on the hospital region because some are re-
search facilitated or has connection to the University,
such as this hospital, who are more inclined to break
barriers, try out new things, do more research.” [p3]
Theme 4. Device positives
Positive opinions of device implementation and uptake
revealed its ease of use, simple instructions and low ad-
verse effects:
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“I just want to add that it's fairly easy for patients to
understand how this works in theory and it's easy for
us, as clinicians, to convince patients to try it be-
cause of the adverse effects are very small. It's easy
for them to administer at home. It's easy for them to
be positive in terms of wanting to try this. I think
that's a huge positive in terms of getting more experi-
ence in using the boot.” [p5]
The device was suggested as a good potential supple-
mentary option for patients unable to engage in alterna-
tive therapies:
“We know that supervised exercise training is the
best, but the problem is that it's not easy to get the
patients do it. It's not always even our option
around, so I think this maybe something that could
be added early on. If that's possible, that would be
great.” [p2]
“I like the theoretical background on this device and
also seen some good clinical results. As a summary,
I'm going to say that it could be a good supplemen-
tary device for treating patients with ischemia.” [p1]
Theme 5. Observed effects and next steps
Clinicians described seeing varied effectiveness from pa-
tient use, yet remained hopeful:
“We have had two patients who had very good effect
of the device. Then we have two patients with inter-
mittent effect of the device and two patients without
any effect of the device.” [p4]
It was stated throughout the focus group that there was
a need for more research as numbers were limited:
“We really need more data to say if there is a proved
effect or not.” [p2]
When discussing price points, a high price was said to
be unrealistic. There were suggestions that Government
subsidies should shoulder medical device costs along
with low contributions from patients, as this was consid-
ered an affordable solution that could benefit more
people:
“Our patients, they don't have that much money, so
the price could not be very high.” [p3]
“I think as well, you need to put this in health bene-
fits frame and maybe it would be better to have a
lower price so that it could be used over a larger
area rather than it be limited by a high price range.”
[p4]
The high cost of amputation was highlighted and how
limb salvage should be a priority when considering re-
search into new medical devices:
“Now, we're back to the limb salvage thing because
that's very important because if you are saving a
limb, it's much less cost than if you have to ampu-
tate.” [p5]
Theme 6. Potential improvements
The final theme reveals a small number though import-
ant opinions on design improvements. Problems arose
with the seal which resulted in a loss of controlled
pressure:
“The problem has been this silicone, as you call it,
that has been porous and patients get leak in use …
” [p4]
There was consensus that it would be beneficial if the
device could be designed for the patient to be able to
move around with the device on rather than having to
sit, as p3 explains:
“You have to sit still in a way for a long time. If you
can move around, it would be more easy to use it.”
[p3]
Other suggested improvements included adding a device
to measure skin blood and creating an adaption for use
on other body parts.
Discussion
This study has provided insight into patient and clinician
experiences and opinions on the use of this novel inter-
mittent negative pressure device that will add descriptive
perspectives to the current evidence base and product
development. The results also demonstrate the complex
interplay and overlap between the themes particularly in
relation to the patient’s positive experiences and per-
ceived outcomes.
Detailed accounts from patients of changes to their
health and lifestyle over disease duration were forefront
throughout interviews. The experience of pain, as well-
documented in lower limb vascular compromise, was
the focal debilitating factor in patients’ sleep quality and
mobility [20, 63–65]. From these personal accounts of
lower limb deterioration, there was clear unease and fear
of amputation; highlighting the significant implications
of physical health impacting mental wellbeing [66, 67].
These life events led patients to take an active incentive
in preventing further personal deterioration and which
facilitated ease in intervention uptake through shared
decision-making.
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The clinicians agreed that amputation was the last re-
sort and that limb salvage was the ultimate primary out-
come for any intervention such as the FlowOx™. When
gathering evidence for such outcomes, the use of ankle-
brachial pressure index as a clinical marker of vascular
status was posited as failing to give results that were
consistent with patient reported improvements. This
aligns with a systematic review of exercise programmes
for intermittent claudication which increase pain-free
walking distances, yet without ankle-brachial pressure
index improvements [46]. Here, intervention efficacy is
evidenced through subjective patient reported outcomes.
Patient reported outcomes are increasingly implemented
as a measure of intervention effectiveness and value in
treatment decision-making [68, 69]. When considering
their own patient reported outcomes, clinicians’ placed
value on these as a valid rationale for continuing device
use. However, the need for objective outcome measures
alongside patient reported outcomes, would provide
clear evidence for the efficacy of this treatment. Data
concerning the clinical efficacy of the FlowOx™ is cur-
rently being compiled for publication. This will allow for
comparisons to be made between patient reported out-
comes and objective measures.
Domestic layout changes and problem solving with de-
vice parts for successful usability displayed active patient
participation and engagement. Experiences of malfunc-
tion with the seal were a source of frustration, however,
device use positives that conveyed ease of use, low ad-
verse effects and perceived symptomatic resolution facil-
itated acceptability for both patients and clinicians.
Patients who were more physically able reported a bur-
den of “lost time” during use, which was associated with
the inability to mobilise. Here exercise programmes may
be a more suitable treatment for these patients, along
with FlowOx™ as an adjunct. In contrast, FlowOx™
proves advantageous in providing a replacement therapy
for those less able to ambulate or attend walking pro-
grammes. When considering such benefits and burden,
limitations exist for direct negative pressure wound ther-
apy and its effects on quality of life during the initial use
phase, including malodour, increased pain and anxiety;
yet QoL is said to improve at therapy end [70]. Early ad-
verse effects of direct negative pressure wound therapy
and intermittent negative pressure use have the potential
to affect compliance, thus determining whether the pre-
scribed therapeutic period is completed for benefit gain.
The participants experiencing INP delivered through
FlowOx™ saw benefits with time and without any of the
limitations reported in initial use negative pressure
wound therapy. As physical activity and exercise pro-
grammes remain the main therapy for peripheral arterial
disease and as a modifiable risk for coronary vascular
disease [71]; both patients and clinicians suggested
design modifications that would allow for some degree
of movement and increased usability.
Patient opinions on perceived effects from use were
mixed, with two experiencing complete symptomatic
resolution, two resolved but unsure if it was the device,
one improved and two minimal/no improvement. These
varied effects from device use were reciprocated with
clinician reports. Patients who had chronic venous con-
ditions experienced less benefit from use when com-
pared to those with peripheral arterial disease.
Clinicians had mixed opinions as to what point in the
disease process would be optimal to implement the de-
vice. These opinions ranged from use in early diagnosis,
as an adjunct or last resort. There was however a con-
sensus for the need to find the most appropriate patient
group through further research involving more partici-
pants. An existing evidence base for FlowOx™ [51–53,
55, 56], along with observed benefits from patients were
well regarded. As researchers, clinicians and medical ed-
ucationalists, they felt it ethically appropriate to imple-
ment novel and evidence-based interventions into their
clinics. This was considered vital for those patients hav-
ing exhausted invasive treatment options that would in-
evitably place the emphasis back on conservative
management [72].
Both patients and clinicians remained hopeful for
others to gain benefit from use, whether facilitated
through continued research, health insurance or with
Government funding. Those patients reporting perceived
benefit actively sought to recommend the device and
give hope to others by reaching through social media,
support groups and in casual conversation. The value
for those having perceived benefits of limb salvage and
as clinicians described, the subsequent societal costs sav-
ings, along with patient reported outcomes in shared de-
cision making, highlight the vital importance of patient
voices in patient centred care [73]; though the positive
benefits identified in this study require further research.
Recent published cost-effective analysis, comparing Flo-
wOx™ home treatment to standard hospital care, has
demonstrated a cost advantage in favour of the home
treatment depending on the severity of the disease [74].
Researchers recognise a lack of common language be-
tween patients and interviewer may be a limitation to
the study. This was addressed through the presence of
an interpreter checking meaning with each patient and
outsourced translation transcribing. We are mindful of
the small number of participants, mixed vascular condi-
tions and limited demographics. However, this study was
exploratory and aimed to gain insight, understanding
and meaning from these purposively sampled partici-
pants rather than to achieve generalisability. To add to
this Norwegian perspective, it is recommended that
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patient and clinician experiences and opinions of Flo-
wOx™ are ascertained in UK health services.
Conclusions
Peripheral vascular diseases have a significant impact on
a person’s functional quality of life. The complex, limit-
ing and costly implications of these conditions now
makes novel intervention research essential. Whilst
using FlowOx™, patients with peripheral arterial disease
experienced significantly more benefit, especially for is-
chaemic ulceration than those with a chronic venous
condition. Clinicians placed value on patient reported
outcomes in the treatment decision-making process.
This preliminary study into experiences of FlowOx™ use
provides valuable feedback that will inform design modi-
fication and ongoing research into implementation
points and prospective user groups.
Exercise, optimal medical treatment and adequate
revascularisation strategies are the recommended state-
of-the-art treatment for chronic limb threatening ischae-
mia. However, some patients continue to have arterial
insufficiency after maximal efforts to revascularise the
limb. These patients often have wounds and comorbidi-
ties which are an obstacle to exercise treatment. Flo-
wOx™ may be a suitable option for such patients as a
conservative therapy that offers a convenient, home use,
self-care management solution for improving symptom-
atic peripheral arterial disease and quality of life.
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